|Home | About | Journals | Submit | Contact Us | Français|
Interstrand cross-links (ICLs) prevent DNA strand separation and, therefore, transcription and replication, making them extremely cytotoxic. The precise mechanism by which ICLs are removed from mammalian genomes largely remains elusive. Genetic evidence implicates ATR, the Fanconi anemia proteins, proteins required for homologous recombination, translesion synthesis, and at least two endonucleases, MUS81-EME1 and XPF-ERCC1. ICLs cause replication-dependent DNA double-strand breaks (DSBs), and MUS81-EME1 facilitates DSB formation. The subsequent repair of these DSBs occurs via homologous recombination after the ICL is unhooked by XPF-ERCC1. Here, we examined the effect of the loss of either nuclease on FANCD2 monoubiquitination to determine if the nucleolytic processing of ICLs is required for the activation of the Fanconi anemia pathway. FANCD2 was monoubiquitinated in Mus81−/−, Ercc1−/−, and XPF-deficient human, mouse, and hamster cells exposed to cross-linking agents. However, the monoubiquitinated form of FANCD2 persisted longer in XPF-ERCC1-deficient cells than in wild-type cells. Moreover, the levels of chromatin-bound FANCD2 were dramatically reduced and the number of ICL-induced FANCD2 foci significantly lower in XPF-ERCC1-deficient cells. These data demonstrate that the unhooking of an ICL by XPF-ERCC1 is necessary for the stable localization of FANCD2 to the chromatin and subsequent homologous recombination-mediated DSB repair.
The XPF-ERCC1 heterodimer is a structure-specific endonuclease that incises double-strand DNA immediately adjacent to a 3′-single-stranded region, removing 3′ overhangs or opening bubbles (12, 69). ERCC1 is required for DNA binding (74), and XPF harbors the catalytic domain (17). XPF-ERCC1 makes the incision 5′ to the lesion during nucleotide excision repair (NER), the pathway responsible for removing helix-distorting DNA lesions (69). Defects in NER cause xeroderma pigmentosum (XP), a syndrome characterized by photosensitivity and a dramatically increased risk of skin cancers due to failure to repair UV photolesions. Cells from all XP complementation groups (XP-A to XP-G) and the recently reported ERCC1-deficient patient (33) are hypersensitive to UV irradiation. However, cells deficient in XPF-ERCC1 differ from other XP cells in that they also are exquisitely sensitive to chemicals that induce DNA interstrand cross-links (ICLs) (13, 28, 54). ICLs are extremely cytotoxic lesions formed when bifunctional agents covalently link both strands of DNA, preventing strand separation, which is necessary for replication or transcription (46). Cross-linking agents such as nitrogen mustards (HN2) (37) and mitomycin C (MMC) (31) produce a mixture of monoadducts and ICLs. However, cytotoxicity correlates with the number of ICLs formed rather than monoadducts (60, 62).
ICLs present a unique challenge to cells, in that they affect both strands of DNA and therefore cannot be repaired by a simple excision and resynthesis mechanism. The mechanism of ICL repair in Escherichia coli is well characterized. It involves the NER complex UvrABC, the recombination repair machinery, or DNA polymerase II-dependent translesion synthesis (6, 7, 9, 75). In Saccharomyces cerevisiae, ICL repair requires both the NER and the homologous recombination (HR) machinery (32). There also is evidence for the involvement of PSO2/SNM1 (25, 26, 66), as well as base excision repair (45), mismatch repair (16), and translesion polymerases (67). ICL repair in mammalian cells, however, remains poorly understood. Genetic evidence implicates XPF-ERCC1 (10), HR proteins such as XRCC2 and XRCC3 (13, 42), MutSβ (82), RPA, PCNA (40, 81), the PSO4 complex (PSO4/PRP19, CDC5L, PLRG1, SPF27) (80), WRN (80), BRCA2 (79), MUS81-EME1 (1, 47), SNM1a, SNM1b (5, 15, 24, 30), and the Fanconi anemia (FA) proteins (4, 18, 68, 73). Of these, the members of the FA family of proteins are unique, in that they appear to be conserved only in higher eukaryotes (11, 34).
FA is a rare and clinically heterogeneous disease characterized by congenital skeletal abnormalities, growth retardation, bone marrow failure, aplastic anemia, genomic instability, and susceptibility to cancer (11, 34). The patients have been grouped into 13 distinct complementation groups (FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM, and FANCN), each representing the deficiency of one protein in the FA pathway. Of these, FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, and FAAP100 and FAAP24, newly discovered components without complementation groups, form the FA core complex (8, 19, 41, 48-51). FANCL is an E3 ubiquitin ligase that monoubiquitinates FANCD2 in response to genotoxic stress (49) during the S phase of the cell cycle (72). FANCI, a newly discovered paralog of FANCD2, which also is monoubiquitinated, forms a chromatin-bound complex with FANCD2. The monoubiquitination of both proteins is required for complex stability and ICL repair (70). FANCD2 monoubiquitination commonly is used as a readout to define which FA proteins act upstream and therefore participate in damage signaling, or are downstream and therefore are more likely to directly contribute to ICL repair. Monoubiquitinated FANCD2 colocalizes with proteins involved in HR, including RAD51 and BRCA1 (14, 20, 72). FANCD1 is identical to BRCA2 (27) and interacts with XRCC3 along with FANCG (29) and RAD51 (43). These data indicate a direct physical interaction between the FA proteins and the HR machinery (78).
The emerging model for the mechanism of ICL repair in mammals suggests that the FA pathway is activated in response to ICL damage in an ATR-dependent manner (3, 64). ATR is activated by blocked replication forks (71) and also phosphorylates numerous downstream effectors, including FA proteins (3, 51, 64) and H2AX (77). Before a replication fork that is blocked by an ICL can be restarted, the ICL must be completely unhooked from one strand of DNA, requiring two incisions 5′ and 3′ of the lesion and potentially producing a DNA double-strand break (DSB) at the fork. MUS81-EME1 is thought to be responsible for the first incision, creating a DSB (22, 23). The second incision, or the unhooking of the cross-link, has been proposed to be a key function of XPF-ERCC1 in ICL repair (56). Once the ICL is completely unhooked from one strand, translesion synthesis can fill the gap, albeit in an error-prone fashion. The repaired strand now can act as a template for reestablishing the replication fork via HR (55).
To further elucidate the mechanism of ICL repair in mammals, it is necessary to define the relationship between the nucleolytic cleavage of cross-linked DNA and the FA pathway. Here, we provide evidence that XPF-ERCC1 nuclease participates in the same ICL repair mechanism as the FA proteins, and that the nucleolytic processing of damaged DNA is not required for FA pathway activation but is required for the stable localization of monoubiquitinated FANCD2 on chromatin.
Human fibroblast lines immortalized by the stable expression of human telomerase, C5RO (normal), XP51RO (XFE), XP42RO (XP-F), and XP25RO (XP-A) (54) were cultured in Ham's F-10 with 10% fetal bovine serum, antibiotics, and nonessential amino acids. Cells were treated for 12 h with 0.3 μM MMC or for 1 h with 3 μM MMC diluted in medium. At the end of the treatment, cells were washed twice with phosphate-buffered saline (PBS), the medium was replaced, and the cells were incubated at 5% CO2 at 37°C under humidity. Time points were calculated with this cell status as 0 h. Wild-type and Ercc1−/− mouse embryonic fibroblasts (MEFs), transformed with simian virus 40 large T antigen, were cultured in a 1:1 mixture of Ham's F-10 and Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum, antibiotics, and nonessential amino acids. Wild-type, Ercc1−/− (53), and Mus81−/− (23) mouse embryonic stem (ES) cells were cultured on gelatin-coated plates in a 1:1 mixture of DMEM and buffalo rat liver (BRL) cell-conditioned medium with 10% FBS, antibiotics, nonessential amino acids, 0.1 mM 2-mercaptoethanol, and leukemic inhibitory factor (1,000 U/ml; Gibco). Wild-type (AA8), UV47 (Xpf mutant), UV96 (Ercc1 mutant), and UV135 (Xpg mutant) CHO cells were grown as a monolayer in Ham's F-12 HEPES medium (Sigma) supplemented with 5 mM glutamine and 10% fetal calf serum (FCS). Cells were grown at 37°C in a 5% CO2 humidified incubator. Cells were treated with 1 μM MMC for 12 h or for 1 h with the stated doses of nitrogen mustard (mechlorethamine hydrochloride; Aldrich) dissolved in culture medium (without FCS) immediately prior to use. Following nitrogen mustard or MMC treatment, media were removed, and cells were washed twice with PBS and returned to the incubator in drug-free complete medium for the stated times.
Cells were trypsinized, washed with PBS, and lysed with 1 ml NETT buffer (100 mM NaCl, 50 mM Tris base, pH 7.5, 5 mM EDTA, pH 8.0, 0.5% Triton X-100) containing Complete mini-protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche Molecular Biochemicals). From each sample, 50 μg protein was resolved on sodium dodecyl sulfate-6% polyacrylamide gel electrophoresis gels. FANCD2 was detected with rabbit anti-FANCD2 (for human cells; 1:10,000; Novus Biologicals), rabbit anti-murine FANCD2 (for mouse cells; 1:1,000), or rabbit anti-FANCD2 (for CHO cells; 1:1,000; Abcam). The loading control used for whole-cell extracts (WCEs) was tubulin (rabbit antitubulin; 1:1,000 or 1:15,000; Abcam and Sigma, respectively). The loading control for cytoplasmic protein from HeLa cells was GRB2 (anti-GRB2; 1:5,000; BD Biosciences). The loading control for chromatin and nuclear fractions of ES cells was TATA binding protein (mouse anti-TBP; 1:500; Abcam) and for hamster cells was ORC2 (mouse anti-ORC2; 1:800; BD-Pharmingen). The loading controls for human fibroblasts and MEFs were nucleophosmin (mouse anti-nucleophosmin; 1:5,000; Millipore) for the soluble nuclear fraction and histone H3 (rabbit anti-H3; 1:20,000; Abcam) for the chromatin fraction. Secondary antibodies used were mouse AP (1:7,500; Promega), rabbit AP (1:1,000; Promega), rat horseradish peroxidase (HRP; 1:5,000; Abcam), rabbit HRP (1:1200; Dako), and mouse HRP (1:1,500 or 1:2,500; Promega).
HeLa cells were obtained from Cancer Research UK Clare Hall Cell Services and maintained in RPMI medium supplemented with 10% FCS and glutamine without antibiotics. Cells were transfected with short interfering RNA (siRNA) duplexes using Hiperfect transfection reagent (Qiagen). Cells were seeded at 50% confluence immediately before the transfection complex (containing 5 nM siRNA oligonucleotides) was added. This transfection step was repeated 24 h later. siRNA-transfected cells were harvested for subsequent drug treatment 72 h after the first transfection. The siRNA duplexes were purchased from Qiagen, and the sequence used to deplete Ercc1 was 5′-GCCCUUAUUCCGAUCUACATT-3′, which has been characterized previously in detail (39). For negative controls, HeLa cells were transfected with Hiperfect with Qiagen AllStars RNA interference negative control duplex.
Cells were plated at 50% confluence and then 16 h later were exposed to 0.3 μM MMC for 12 h or were left untreated. At 12, 24, 48, and 72 h after exposure, the cells were fixed with ice-cold 70% ethanol and stored at 4°C overnight. CHO cells were treated with 5 μM HN2 as described above, and samples were removed at the stated times for fixing. The fixed cells were washed with PBS, treated with RNase A (Roche) at a final concentration of 100 U/ml for 30 min at room temperature, and then stained with 1 μg/ml propidium iodide in PBS. Cell cycle analysis was performed on a Dako MoFlo flow cytometer or a Becton Dickinson FACSCalibur.
The modified version of the comet assay for the detection of ICLs was performed exactly as previously described (13).
Cells were fractionated into cytosolic, nuclear, and chromatin fractions with a modification of a published protocol (35). In brief, cells were trypsinized, pelleted, and washed twice with PBS. The pellet was vortexed at full speed for 15 s with 200 μl of CERI reagent from the Pierce NE-PER fractionation kit (Pierce Biotech) with Complete mini-protease inhibitor cocktail and then was incubated on ice for 10 min. This was followed by the addition of 11 μl of CERII, vortexing for 5 s, and incubation on ice for 1 min. The mixture was spun down at 13,000 rpm for 5 min, and the supernatant was collected as the cytosolic fraction. The nuclei were suspended in extraction buffer (15 mM Tris-HCl, pH 7.3, 1 mM EDTA, 0.4 M NaCl, 1 mM MgCl2, 10% glycerol, 10 mM β-mercaptoethanol, and Complete mini-protease inhibitor cocktail), mixed for 1 h at 4°C, and spun down at 13,000 rpm for 10 min. The supernatant was collected as the soluble nuclear fraction, and the pellet was suspended in micrococcal nuclease buffer (20 mM Tris·HCl, pH 7.5, 100 mM KCl, 2 mM MgCl2, 1 mM CaCl2, 0.3 M sucrose, 0.1% Triton X-100, and Complete mini-protease inhibitor cocktail) and digested with 400 U/ml S7 micrococcal nuclease (Roche) at 37°C for 30 min. The reaction was spun down at 13,000 rpm for 10 min, and supernatant was collected as the chromatin fraction. For CHO and HeLa cells, fractionation was performed exactly as described previously (65).
C5RO and XP51RO human fibroblasts (54) were plated on glass coverslips at 50% confluence and then 16 h later were exposed to 3 μM MMC for 1 h or left untreated. At 6, 12, 24, and 48 h following exposure, cells were fixed as described previously (76) with some modifications. Briefly, cells were washed with PBS, permeabilized with ice-cold 0.5% Triton X-100 in PBS, and then fixed with 2% paraformaldehyde and blocked with 5% bovine serum albumin at room temperature. FANCD2 was detected by incubation with rabbit polyclonal anti-FANCD2 antibody (1:1,000; Novus Biologicals) for 90 min at room temperature and then with goat anti-rabbit antibody-Alexa-488 (1:1,000; Invitrogen). Images were taken of 20 fields of cells for each genotype. The total number of nuclei and the number of nuclei with foci were counted in each field. The sum from all fields was used to calculate the percent of nuclei with foci. The experiment was done in triplicate. Student's t test was used to probe significant differences between cell lines.
To determine if XPF-ERCC1 deficiency affects the activation of the FA pathway, FANCD2-L (monoubiquitinated form) and FANCD2-S (nonubiquitinated form) were measured in mutant cells exposed to cross-linking agents. Wild-type and Ercc1 mutant CHO cells were exposed to the cross-linking agent nitrogen mustard (HN2) for 1 h, and then WCEs were collected 18 or 24 h later. The levels of FANCD2-L were increased similarly in both cell types after exposure to HN2 relative to the levels for untreated samples (Fig. (Fig.1A).1A). This was confirmed in an isogenic pair of human cell lines by knocking down ERCC1 expression in HeLa cells using siRNA and exposing them to a different cross-linking agent, MMC (Fig. (Fig.1B1B and data not shown). Comparable results were obtained with Ercc1−/− MEFs exposed to MMC (Fig. (Fig.1C).1C). Since XPF-ERCC1 nuclease appeared not to be required for FA pathway activation, we also screened cells deficient in MUS81, a second nuclease required for ICL repair (23). Mouse ES cells genetically deleted for either Ercc1 or Mus81 were exposed to MMC for 1 h, and then WCEs were collected 24 h later. The immunodetection of FANCD2 revealed increased levels of FANCD2-L in all cells exposed to the cross-linking agents relative to those of the untreated cells (Fig. (Fig.1D).1D). These data demonstrate that FANCD2 is monoubiquitinated in response to cross-link damage in the absence of XPF-ERCC1 or MUS81-EME1. This indicates that the nucleolytic processing of cross-links by MUS81-EME1 or XPF-ERCC1 is not necessary for FA pathway activation, as defined by FANCD2 monoubiquitination.
Although FANCD2 is monoubiquitinated in XPF-ERCC1-deficient cells, initial data from the MEFs suggested that FANCD2-L levels remained elevated longer in Ercc1−/− cells exposed to MMC than in wild-type cells (Fig. (Fig.1C).1C). To investigate this further, wild-type and mutant CHO cells and human fibroblasts were exposed to MMC or HN2, and FANCD2 was visualized by immunoblotting at multiple time points following DNA damage. Both MMC and HN2 induced an increase in the ratio of FANCD2-L to FANCD2-S in wild-type and NER-deficient Xpg mutant CHO cells (Fig. (Fig.2A).2A). By 48 h after HN2 or MMC exposure, FANCD2-L levels returned to near normal in these cell lines. In contrast, the ratio of FANCD2-L to FANCD2-S still was elevated in both Xpf and Ercc1 mutant CHO cells at 48 h after exposure to HN2 or MMC (Fig. (Fig.2A).2A). The results were recapitulated in cells derived from human XP patients (Fig. (Fig.2B).2B). In wild-type and NER-deficient XP-A human fibroblasts, MMC induced a rapid increase in the ratio of FANCD2-L to FANCD2-S that persisted for 24 h. The levels of monoubiquitinated FANCD2 returned to those of untreated cells by 48 h. In two different XP-F cell lines, the ratio of FANCD-L to FANCD2-S was increased by MMC, as was the case in wild-type cells. However, in the XPF-ERCC1-deficient cells, the ratio of FANCD2-L to FANCD-S remained elevated at 48 h after exposure to MMC (Fig. (Fig.2B).2B). This suggests that in the absence of XPF-ERCC1, the FA pathway remains activated in response to cross-link damage.
Because FANCD2 monoubiquitination is cell cycle dependent (36), the cell cycle profile of the CHO cell lines was measured at multiple time points after exposure to cross-linking agents (Fig. (Fig.2C).2C). HN2 and MMC caused an accumulation of cells in S and G2/M phases at 12 and 18 h in all cells. By 48 h following MMC treatment, some wild-type and Xpg mutant cells had escaped G2/M arrest, but XPF-ERCC1-defective cells remained arrested in late S and G2/M. Therefore, persistent FANCD2-L correlates with G2/M accumulation. The Xpg mutant cells were somewhat slower to escape the G2/M arrest than wild-type cells, and this might be attributable to the role of NER in repairing the monoadducts produced by cross-linking agents. The persistence of FANCD2-L also correlates with the impaired unhooking of cross-link damage (Fig. (Fig.2D).2D). The modified comet assay (13) was used to measure the nucleolytic processing of cross-link damage in CHO cells following HN2 exposure. In wild-type and Xpg mutant cells, cross-link unhooking was greater than 85% at 48 h. In contrast, in the Ercc1 and Xpf mutant cells in which FANCD2 monoubiquitination persisted, cross-link unhooking was only approximately 40% at 48 h. These data indicate that the nucleolytic processing of ICLs coincides with the deactivation of the FA pathway, which was marked by a decrease in the FANCD2-L/FANCD2-S ratio and is associated with escape from G2/M.
Another way to quantify FA pathway activation is to measure chromatin-bound FANCD2 (61). Surprisingly, in human fibroblasts the number of cells with FANCD2 foci was significantly reduced in the XPF-ERCC1-deficient cell line (Fig. (Fig.3).3). We measured FANCD2 foci in human fibroblasts exposed to MMC after the detergent extraction of soluble proteins. FANCD2 foci were detected in approximately 15% of untreated wild-type and XPF mutant cells. Twelve hours after exposure to MMC, 40% of wild-type cells had FANCD2 foci, whereas 29% of XPF mutant cells had foci (P = 0.025), and 24 h after the exposure 42% of wild-type cells and 36% of XPF mutant cells had FANCD2 foci (P = 0.001). By 48 h after cross-link damage, the fraction of cells with FANCD2 foci had returned to normal in both cell types. These data suggest that although FANCD2 is efficiently ubiquitinated in XPF-ERCC1-deficient cells in response to cross-link damage, the localization of FANCD2 to the chromatin is impaired, a critical step for the subsequent HR-mediated repair of replication-induced DSBs.
FANCD2 levels were normal in XPF-ERCC1-deficient cells exposed to cross-linking agents, yet chromatin-bound FANCD2 focus formation was diminished, suggesting the aberrant subcellular localization of FANCD2 in the absence of this nuclease. To further explore this, ERCC1 was depleted in HeLa cells by siRNA; the cells then were exposed to HN2 and fractionated. The immunodetection of FANCD2 in WCEs revealed that, as previously observed (Fig. (Fig.1B),1B), FANCD2 was efficiently monoubiquitinated in both control and ERCC1-depleted cells (Fig. (Fig.4A).4A). In control cells, the level of FANCD2-L in the chromatin fraction increased dramatically following the exposure of the cells to HN2 (Fig. (Fig.4A).4A). In contrast, in ERCC1-depleted cells, the amount of FANCD2-L in the chromatin fraction did not increase following the exposure of cells to HN2 but instead was elevated in the soluble nuclear fraction (Fig. (Fig.4A4A).
In human fibroblasts, the level of FANCD2-L was comparable for XP-F and wild-type cells before and after exposure to MMC (Fig. (Fig.4B).4B). However, the amount of FANCD2 detected in the chromatin fraction of XP-F fibroblasts treated with MMC was substantially lower than that detected in normal human fibroblasts (Fig. (Fig.4B).4B). This is consistent with the observation that XP-F cells had significantly fewer FANCD2 foci than wild-type cells after MMC treatment (Fig. (Fig.3).3). Similar results were obtained using congenic Ercc1−/− MEFs exposed to MMC (Fig. (Fig.4C),4C), where again there was less chromatin-bound FANCD2 in the knockout cells than in the wild type in response to cross-link damage. The subcellular localization of FANCD2 was less dramatically affected in ES cells (Ercc1−/− and Mus81−/−) than fibroblasts (Fig. (Fig.4D).4D). One possible explanation is that ES cells differ dramatically from fibroblasts in their cell cycle profile and checkpoint responses to cross-link damage (data not shown). Finally, an equivalent level of FANCD2-L was detected in wild-type and Xpf mutant CHO cells exposed to HN2 (Fig. (Fig.4E).4E). However, substantially less FANCD2-L was detected in the chromatin fraction of the mutant cells. In contrast, the chromatin localization of FANCD2-L was not impaired in Xpf mutant cells exposed to ionizing radiation (Fig. (Fig.4E).4E). This indicates that the aberrant subcellular localization of FANCD2-L seen in XPF-ERCC1-deficient cells was specific for ICLs and not other forms of DNA damage, such as direct DSBs, where XPF-ERCC1 is not required prior to HR-mediated repair (2).
Taken together, these data, obtained from three mammalian cell systems exposed to two different cross-linking agents, support the conclusion that FANCD2 is not stably localized to the chromatin in the absence of XPF-ERCC1. This suggests that the nucleolytic processing of cross-link damage is required for the stable accumulation of FANCD2 at or near the sites of damage. The data also imply that FANCD2 monoubiquitination does not always correlate with chromatin localization and should be considered distinct steps in the response to cross-link damage.
Two sets of proteins that are critical for the response to and repair of ICLs are the FA family of proteins and the XPF-ERCC1 complex (46, 55). Whether or not these proteins function in the same DNA damage detection and repair mechanism has not been established. A significant body of biochemical and cellular data indicates an essential role for XPF-ERCC1 endonuclease in the unhooking of ICLs (13, 38). However, it is not known if the unhooking of ICLs must occur prior to the activation of the FA pathway. Our studies revealed that XPF-ERCC1 nuclease is not required for the activation of the FA pathway, as defined by the monoubiquitination of FANCD2. In the same experiments, we confirmed that both XPF and ERCC1 are required for efficient ICL unhooking by using the modified comet assay. Thus, the nucleolytic processing of ICLs by XPF-ERCC1 is not a prerequisite for FA pathway activation. This is consistent with the results of numerous other laboratories, indicating that replisome stalling at DNA lesions and secondary structures, as occurs with ICLs, is sufficient to generate the signal that ultimately leads to FANCD2 ubiquitination (11, 21, 52). Given that ATR activation also is required for the timely ubiquitination of FANCD2 in response to ICLs (3), it is tempting to speculate that tracts of single-stranded DNA that occur at stalled replisomes are what trigger ATR-dependent FANCD2 monoubiquitination. In the case of ICLs, single-stranded DNA likely results from the nucleolytic processing of stalled forks rather than the uncoupling of leading and lagging strand synthesis (63), which is what activates ATR when replication is blocked by lesions that affect only one strand of DNA.
Although the XPF-ERCC1-dependent nucleolytic processing of ICLs is not required for FA pathway activation, our data did reveal a difference in the kinetics of FANCD2 modification in XPF-ERCC1-deficient cells. These nuclease-deficient cells show a persistence of monoubiquitinated FANCD2 in WCEs following ICL induction. In contrast to our results, McCabe et al. reported the decreased monoubiquitination of FANCD2 in cells depleted of ERCC1 by siRNA (44). However, like us, these authors did observe that MMC causes an induction of FANCD2 monoubiquitination in ERCC1-depleted cells, and that the relative increase in the ratio of FANCD2-L to FANCD2-S was similar in ERCC1-depleted and control cells upon cross-link damage. We observed persistent FANCD2 monoubiquitination in XPF-ERCC1-deficient cells from three species in response to two different cross-linking agents. Prolonged FANCD2 monoubiquitination has not been reported in other cross-link sensitive mutants previously, suggesting that the incision of cross-linked DNA by XPF-ERCC1 is essential for the repair of ICLs and the termination of the DNA damage response.
In addition, the chromatin localization of FANCD2 in response to cross-link damage is impaired in XPF-ERCC1-deficient cells, as demonstrated by cellular fractionation and FANCD2 foci formation. This suggests that the stable association of monoubiquitinated FANCD2 with chromatin requires (at a minimum) an unhooked ICL. Indeed, the persistent FANCD2-L observed in Xpf and Ercc1 mutant WCEs might reflect continued attempts to target FANCD2 to sites of damage in chromatin, which are nonproductive when cross-linked DNA is not incised.
The XPF-ERCC1-related nuclease MUS81-EME1 also is implicated in ICL repair by virtue of the hypersensitivity of Mus81−/− and Eme1−/− mouse cells to cross-linking agents (23). Specifically, MUS81 is required for the cleavage of replication forks stalled by ICLs, producing DSBs with one accessible end (22, 23). However, the ICL-induced monoubiquitination of FANCD2 is normal in Mus81−/− cells (Fig. (Fig.1),1), and the genetic disruption of FANCB and MUS81 does not render cells hypersensitive to cross-linking agents relative to the deletion of FANCB alone (59). These data support the conclusion that the generation of DSBs at ICLs during S phase by MUS81-EME1 is not a prerequisite for the activation of FANCD2. Taken together, these data suggest a model for ICL repair (Fig. (Fig.5;5; also see a recent review by Thompson and Hinz ) in which the stalling of a replication fork at an ICL leads to the formation of a DSB created by MUS81-EME1 nuclease. Fork stalling, but not the generation of a DSB, is sufficient for the activation of ATR and the monoubiquitination of FANCD2. However, in the absence of the unhooking of the ICL by XPF-ERCC1, FANCD2 and, therefore, presumably the HR machinery do not stably associate at the sites of damage. This results in failure to repair ICL-dependent DSBs in XPF-ERCC1-deficient cells (56).
The data presented herein demonstrate that there is not an absolute correlation between the level of monoubiquitinated FANCD2 and its chromatin association. In XPF-ERCC1-deficient cells in which ICL-dependent DSBs are not repaired (56), the levels of monoubiquitinated FANCD2 persist longer than in wild-type cells after cross-link damage, but the chromatin localization of FANCD2 is reduced. This suggests that in the absence of ICL repair, damage signaling persists. In accordance, it was reported recently that FANCD2 deubiquitination by USP1 (58) is required for efficient ICL repair (61). Thus, when the chromatin association of FANCD2 is compromised, for instance in the absence of ICL unhooking by XPF-ERCC1, the deubiquitination of FANCD2 by USP1 does not occur. This is supported by the observation that FANCD2 deubiquitination is concurrent with the release of FANCD2 from chromatin (61). The eviction of FANCD2 from chromatin likely coincides with the recruitment of factors that are undertaken after unhooking steps of ICL repair, including HR-mediated DSB repair and translesion synthesis to fill the gap created by ICL unhooking (57, 76).
L.J.N. and N.R.B. were supported by The Ellison Medical Foundation (AG-NS-0303-05) and NCI (CA111525-03). A.O. was supported by ECMC, and A.T.W. was supported by a New Zealand Top Achiever Scholarship. Research in P.M.'s laboratory is funded by Cancer Research UK. Work in the R.K. laboratory was supported by The Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NWO) and the European Commission (Integrated Project 512113).
Published ahead of print on 5 October 2009.